- Home
- CWAN vs LNTH Comparison
CWAN vs LNTH Comparison
Compare CWAN & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWAN
- LNTH
- Stock Information
- Founded
- CWAN 2004
- LNTH 1956
- Country
- CWAN United States
- LNTH United States
- Employees
- CWAN N/A
- LNTH N/A
- Industry
- CWAN Computer Software: Prepackaged Software
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CWAN Technology
- LNTH Health Care
- Exchange
- CWAN Nasdaq
- LNTH Nasdaq
- Market Cap
- CWAN 6.1B
- LNTH 5.7B
- IPO Year
- CWAN 2021
- LNTH 2015
- Fundamental
- Price
- CWAN $22.06
- LNTH $81.26
- Analyst Decision
- CWAN Buy
- LNTH Strong Buy
- Analyst Count
- CWAN 10
- LNTH 5
- Target Price
- CWAN $31.50
- LNTH $131.20
- AVG Volume (30 Days)
- CWAN 4.1M
- LNTH 903.4K
- Earning Date
- CWAN 07-30-2025
- LNTH 07-30-2025
- Dividend Yield
- CWAN N/A
- LNTH N/A
- EPS Growth
- CWAN N/A
- LNTH N/A
- EPS
- CWAN 1.71
- LNTH 3.53
- Revenue
- CWAN $475,948,000.00
- LNTH $1,536,699,000.00
- Revenue This Year
- CWAN $63.43
- LNTH $4.63
- Revenue Next Year
- CWAN $29.94
- LNTH $9.35
- P/E Ratio
- CWAN $12.87
- LNTH $23.01
- Revenue Growth
- CWAN 23.21
- LNTH 12.53
- 52 Week Low
- CWAN $18.75
- LNTH $73.11
- 52 Week High
- CWAN $35.71
- LNTH $126.89
- Technical
- Relative Strength Index (RSI)
- CWAN 46.53
- LNTH 49.75
- Support Level
- CWAN $21.68
- LNTH $78.74
- Resistance Level
- CWAN $22.92
- LNTH $85.31
- Average True Range (ATR)
- CWAN 0.66
- LNTH 2.31
- MACD
- CWAN 0.04
- LNTH 0.36
- Stochastic Oscillator
- CWAN 43.46
- LNTH 41.30
About CWAN Clearwater Analytics Holdings Inc.
Clearwater Analytics describes its mission as aiming to be the world's most trusted and comprehensive technology platform for the entire investment cycle. Clearwater has historically focused on back-office functions such as investment accounting, but with acquisitions such Enfusion, Beacon, and Bistro, the firm has broadened its focus with front-office and middle-office capabilities. Clearwater primarily serves insurance companies, asset managers, hedge funds, and corporate treasuries. Pro forma for Enfusion, about 76% of Clearwater's revenue is generated in the US.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.